Logo

Rosetta Genomics Licenses Roche’s PCR Technology for miRNA Dx Products

Jan 07, 2008
NEW YORK (GenomeWeb News) - Rosetta Genomics said today it has licensed PCR technology from Roche Molecular Diagnostics for use in its microRNA-based diagnostic tests.
 
The company plans to use the PCR technology in its efforts to identify microRNA biomarkers in several different sample types and body fluids.
 
Rosetta Genomics a month ago struck a license agreement with Nanogen for its MGB Probe technology, which it also plans to use in the development of its line of diagnostic tests.
 
Rosetta has said that in 2008 it plans to launch diagnostic tests for squamous and non-squamous lung cancers, for mesothelioma and lung adenocarcinoma, and to identify the origin of tumors.
 
Financial terms of the agreement were not released.

Breaking News
The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.